FibroBiologics (NASDAQ: FBLG) appeals Nasdaq move to delist its shares
Rhea-AI Filing Summary
FibroBiologics, Inc. reports that Nasdaq’s Listing Qualifications staff issued a Staff Determination on July 22, 2026 to delist its securities from The Nasdaq Capital Market. The notice cites noncompliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
The company’s bid price closed below $1.00 for 30 consecutive business days from June 8 through July 21, 2026. Because FibroBiologics effected a reverse stock split within the prior year, it is not eligible for the usual 180-day cure period under Nasdaq Listing Rule 5810(c)(3)(A)(iv). Unless it requests an appeal by July 29, 2026, trading is expected to be suspended at the opening of business on July 31, 2026. FibroBiologics intends to timely request a hearing before a Nasdaq Hearings Panel, which will stay delisting actions during the hearing process, but there is no assurance the appeal or any plan to regain compliance will succeed.
Positive
- None.
Negative
- Nasdaq issued a Staff Determination to delist FibroBiologics after its bid price stayed below $1.00 for 30 consecutive business days, with no 180-day cure period available due to a recent reverse stock split.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Key Figures
Minimum Bid Price Requirement: $1.00 per share
Noncompliance Period: 30 consecutive business days
Staff Determination Date: July 22, 2026
+2 more
5 metrics
Minimum Bid Price Requirement
$1.00 per share
Required under Nasdaq Listing Rule 5550(a)(2) for continued listing
Noncompliance Period
30 consecutive business days
Bid price closed below $1.00 from June 8 through July 21, 2026
Staff Determination Date
July 22, 2026
Date Nasdaq Listing Qualifications staff issued delisting determination
Appeal Request Deadline
July 29, 2026
Latest date to request a hearing before a Nasdaq Hearings Panel
Scheduled Suspension Date
July 31, 2026
Date securities would be suspended at market open absent an appeal
Key Terms
Nasdaq Listing Rule 5550(a)(2), Bid Price Rule, reverse stock split, Nasdaq Hearings Panel, +1 more
5 terms
Nasdaq Listing Rule 5550(a)(2) regulatory
"not in compliance with Nasdaq Listing Rule 5550(a)(2)"
Bid Price Rule regulatory
"which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”)"
reverse stock split financial
"not eligible for any such compliance period... due to the fact that the Company has effected a reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Nasdaq Hearings Panel regulatory
"request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
Staff Determination regulatory
"received a Staff Determination letter (the “Staff Determination”) from the Listing Qualifications Department"
A staff determination is a formal decision or finding made by agency or company employees who handle reviews and enforcement, rather than by higher-level boards or executives. Think of it like a referee’s ruling during a game: it resolves a specific procedural or compliance question and can affect whether a filing, claim, or product moves forward, the timing of approvals, and potential legal or market consequences for investors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What triggered Nasdaq’s delisting notice for FibroBiologics (FBLG)?
Nasdaq staff moved to delist FibroBiologics after its bid price stayed below $1.00 per share for 30 consecutive business days, from June 8 through July 21, 2026, violating Nasdaq Listing Rule 5550(a)(2) on minimum bid price.
Why doesn’t FibroBiologics (FBLG) get a 180-day cure period from Nasdaq?
FibroBiologics is not eligible for the usual 180-day cure period because it effected a reverse stock split within the prior year, as referenced under Nasdaq Listing Rule 5810(c)(3)(A)(iv) governing minimum bid price deficiencies.
What deadlines does FibroBiologics (FBLG) face regarding Nasdaq delisting?
FibroBiologics must request an appeal by July 29, 2026, or its securities are scheduled to be suspended and delisted from The Nasdaq Capital Market at the opening of business on July 31, 2026, according to Nasdaq staff.
How does FibroBiologics (FBLG) plan to respond to Nasdaq’s delisting action?
FibroBiologics intends to timely request a hearing before a Nasdaq Hearings Panel, present a plan to regain compliance, and monitor its closing bid price while evaluating options to address the Bid Price Rule deficiency.
Does a hearing guarantee FibroBiologics (FBLG) will stay listed on Nasdaq?
No. A timely hearing request will temporarily stay delisting actions during the process, but the company states there can be no assurance the Panel will grant continued listing or that it can regain or maintain compliance.